|
1.
|
Jemal A, Siegel R, Ward E, et al: Cancer
Statistics 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar
|
|
2.
|
Almoguera C, Shibata D, Forrester K, et
al: Most human carcinomas of the exocrine pancreas contain mutant
c-K-ras genes. Cell. 53:549–554. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kokawa A, Kondo H, Gotoda T, et al:
Increased expression of cyclooxygenase-2 in human pancreatic
neoplasms and potential for chemoprevention by cyclooxygenase
inhibitors. Cancer. 91:333–338. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Tucker ON, Dannenberg AJ, Yang EK, et al:
Cyclooxygenase-2 expression is upregulated in human pancreatic
cancer. Cancer Res. 59:987–990. 1999.PubMed/NCBI
|
|
5.
|
Okami J, Yamamoto H, Fujiwara Y, et al:
Overexpression of COX-2 in carcinoma of the pancreas. Clin Cancer
Res. 5:2018–2024. 1999.PubMed/NCBI
|
|
6.
|
Osada M, Tolkacheva T, Li W, et al:
Differential roles of Akt, Rac, and Ral in R-Ras-mediated cellular
transformation, adhesion, and survival. Mol Cell Biol.
19:6333–6344. 1999.
|
|
7.
|
Krysan K, Reckamp KL, Dalwadi H, et al:
Prostaglandin E2 activates mitogen-activated protein kinase/Erk
pathway signaling and cell proliferation in non-small cell lung
cancer cells in an epidermal growth factor receptor-independent
manner. Cancer Res. 65:6275–6281. 2005. View Article : Google Scholar
|
|
8.
|
Han W and Ca T: Cyclooxygenase-2-derived
prostaglandin E2 promotes human cholangiocarcinoma cell growth and
invasion through EP1 receptor-mediated activation of the epidermal
growth factor receptor and Akt. J Biol Chem. 280:24053–24063. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Sparano JA, Moulder S, Kazi A, et al:
Phase II trial of tipifarnib plus neoadjuvant
doxorubicin-cyclophosphamide in patients with clinical stage
IIB-IIIC breast cancer. Clin Cancer Res. 15:2942–2948. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lancet JE, Gojo I, Gotlib J, et al: A
phase 2 study of the farnesyltransferase inhibitor tipifarnib in
poor-risk and elderly patients with previously untreated acute
myelogenous leukemia. Blood. 109:1387–1394. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Moller I, Blum S, Gattermann N, Haas R,
Habersang U and Kuendgen A: Repeated responses of an elderly
patient with high-risk myelodysplastic syndrome to sequential
therapy with tipifarnib, 5-azacitidine, and dectabine. Ann Hematol.
88:1141–1144. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Van Cutsem E, van de Velde H, Karasek P,
et al: Phase III trial of gemcitabine plus tipifarnib compared with
gemcitabine plus placebo in advanced pancreatic cancer. J Clin
Oncol. 22:1430–1438. 2004.PubMed/NCBI
|
|
13.
|
Hansson A, Marin YE, Suh J, et al:
Enhancement of TPA-induced growth inhibition and apoptosis in
myeloid leukemia cells by BAY 11-7082 an NF-κB inhibitor. Int J
Oncol. 27:941–948. 2005.PubMed/NCBI
|
|
14.
|
Zheng X, Chang RL, Cui XX, et al:
Inhibitory effect of 12-O-tetradecanoylphorbol-13-acetate alone or
in combination with all-trans-retinoic acid on the growth of LNCaP
prostate tumors in immunodeficient mice. Cancer Res. 64:1811–1820.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Kunnumakkara AB, Krishnan S, Diagaradjane
P, Gelovani J and Aggarwal BB: Curcumin potentiates antitumor
activity of gemcitabine in an orthotopic model of pancreatic cancer
through suppression of proliferation, angiogenesis, and inhibition
of nuclear factor-kappaB-regulated gene products. Cancer Res.
67:3853–3861. 2007. View Article : Google Scholar
|
|
16.
|
Bakeman A: Recommended effect size
statistics for repeated measures designs. Behav Res Methods.
37:379–384. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Stoline MR: The status of multiple
comparisons, simultaneous estimation of all pairwise comparisons in
one-way ANOVA designs. Am Stat. 35:134–141. 1981.
|
|
18.
|
Zheng X, Chang RL, Cui XX, et al: Effects
of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with
paclitaxel (Taxol) on prostate cancer LNCaP cells cultured in vitro
or grown as xenograft tumors in immunodeficient mice. Clin Cancer
Res. 12:3444–3451. 2006. View Article : Google Scholar
|
|
19.
|
End DW, Smets G, Todd AV, et al:
Characterization of the antitumor effects of the selective farnesyl
protein transferase inhibitor R115777 in vivo and in vitro. Cancer
Res. 61:131–137. 2001.PubMed/NCBI
|
|
20.
|
Macdonald JS, McCoy S, Whitehead RP, et
al: A phase II study of farnesyl transferase inhibitor R115777 in
pancreatic cancer: a Southwest Oncology Group (SWOG 9924) study.
Invest New Drugs. 23:485–487. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Cohen SJ, Ho L, Ranganathan S, et al:
Phase II and pharmaco-dynamic study of the farnesyltransferase
inhibitor R115777 as initial therapy in patients with metastatic
pancreatic adenocarcinoma. J Clin Oncol. 21:1301–1306. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Sun J, Ohkanda J, Coppola D, et al:
Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast
carcinoma apoptosis and tumor regression in H-Ras transgenic mice.
Cancer Res. 63:8922–8929. 2003.PubMed/NCBI
|
|
23.
|
Malinowski JM: Atorvastatin, a
hydroxymethylglutarylcoenzyme A reductase inhibitor. Am J Health
Syst Pharm. 55:2253–2303. 1998.PubMed/NCBI
|
|
24.
|
Goldstein JL and Brown MS: Regulation of
the mevalonate pathway. Nature. 343:425–430. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Wiemer AJ and Wiemer DF: The intermediate
enzymes of isoprenoid metabolism as anticancer targets. Anticancer
Agents Med Chem. 9:526–542. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ding XZ, Hennig R and Adrian TE:
Lipoxygenase and cyclooxygenase metabolism: new insights in
treatment and chemoprevention of pancreatic cancer. Mol Cancer.
2:10–16. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
El-Rayes BF, Ali S, Sarkar FH and Philip
PA: Cyclooxygenase-2-dependent and -independent effects of
celecoxib in pancreatic cancer cell lines. Mol Cancer Ther.
3:1421–1426. 2004.PubMed/NCBI
|
|
28.
|
Raut CP, Nawrocki S, Lashinger LM, et al:
Celecoxib inhibits angiogenesis by inducing endothelial cell
apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther.
3:1217–1224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Wei D, Wang L, He Y, Xiong HQ, Abbruzzese
JL and Xie K: Celecoxib inhibits vascular endothelial growth factor
expression in and reduces angiogenesis and metastasis of human
pancreatic cancer via suppression of Sp1 transcription factor
activity. Cancer Res. 64:2030–2038. 2004. View Article : Google Scholar
|
|
30.
|
Gregor JI, Kilian M, Heukamp I, et al:
Effects of selective COX-2 and 5-LOX inhibition on prostaglandin
and leukotriene synthesis in ductal pancreatic cancer in Syrian
hamster. Prostaglandins Leukot Essent Fatty Acids. 2:226–232.
2005.PubMed/NCBI
|
|
31.
|
Colby JK, Klein RD, McArthur MJ, et al:
Progressive meta-plastic and dysplastic changes in mouse pancreas
induced by cyclooxygenase-2 overexpression. Neoplasia. 10:782–796.
2008.PubMed/NCBI
|
|
32.
|
Glasgow RE and Mulvihill SJ: Pancreas.
Surgery, Basic Science and Clinical Evidence. Norton JA, Barie PS,
Bollinger RR, et al: 2nd edition. Springer; New York, NY: pp.
875–909. 2008
|
